CD4 and lung cancer: Indeed, studies have reported incremental changes to biomarkers of immunosenescence following repeated administration of chemotherapy, including lower ratios of CD4+ T cells to CD8+ T cells and accumulations of CD28− and CD57+ cells in patients with breast and lung cancer [166, 172].